Releases
15. May, 2025
Financial Report Q1-2025
The Company has advanced well with its planned activities Positive CT001 MDR assessment Finalization...
Releases
30. April, 2025
Recruitment has completed in the Paediatric Study 0202
30150 paediatric patients have been recruited in Study 0202 as planned Study 0202 is...
Releases
Facts
6. March, 2025
Paediatric ED pain is still undertreated – the need for training and more treatment options
Pediatric pain management is a constantly developing field. Despite extensive research, several studies have...
Releases
28. February, 2025
Annual Report 2024
Today, Friday 28. February, Cessatech has released the Annual Report for 20024. We have...
Releases
4. February, 2025
Positive Notified Body opinion under MDR for CT001
On 4 February – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company...
Releases
16. October, 2024
Halfway milestone patient recruitment in Paediatric Study 0202
Cessatech announces that recruitment has today reached the halfway point for patient recruitment with...
Releases
26. August, 2024
Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001
Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding...
Releases
12. August, 2024
Cessatech extends Loan Facility Agreement to DKK 10 million…
Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the...
Releases
5. July, 2024
Anders Dyhr Dombernowsky-Toft appointed to the Board of Directors
Cessatech has today appointed Anders Dyhr Dombernowsky-Toft to the Board of Directors at the...
Releases
28. June, 2024
New data on paediatric pain relief at the PAGE conference in Rome favouring its lead candidate CT001
On 28 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the presentation...
Releases
3. June, 2024
Cessatech announces superior simulated pain efficacy in children
Cessatech announces the final simulated efficacy data in children with CT001 from the abstract...